Get the Stockscreener App
1.41
2.92%
+0.04
InflaRx N.V. stock is currently priced at $1.41, with a 24-hour trading volume of 197.27K.
It has seen a +2.92% increased in the last 24 hours and a -7.24% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.38 pivot point. If it approaches the $1.43 resistance level, significant changes may occur.
Previous Close:
$1.37
Open:
$1.365
24h Volume:
197.27K
Market Cap:
$83.03M
Revenue:
-
Net Income/Loss:
$-46.12M
P/E Ratio:
-1.8881
EPS:
-0.7468
Net Cash Flow:
$-41.02M
1W Performance:
+3.68%
1M Performance:
-7.24%
6M Performance:
-12.96%
1Y Performance:
-72.41%
1D Range:
$1.33
$1.43
52W Range:
$1.14
$5.20
InflaRx N.V. Stock (IFRX) Company Profile
Name
InflaRx N.V.
Sector
Industry
Phone
49 3641 508 180
Address
Winzerlaer Strasse 2, Jena
InflaRx N.V. Stock (IFRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-05-23 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-28-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-06-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-08-20 | Initiated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Apr-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-05-19 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-05-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-05-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Jun-05-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-05-19 | Downgrade | SunTrust | Buy → Hold |
| Jan-29-19 | Initiated | Robert W. Baird | Outperform |
| Dec-10-18 | Initiated | Credit Suisse | Outperform |
| Jul-13-18 | Initiated | BMO Capital Markets | Outperform |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-28-18 | Initiated | SunTrust | Buy |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
InflaRx N.V. Stock (IFRX) Latest News
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
GlobeNewswire Inc.
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
GlobeNewswire Inc.
Why Tellurian Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Benzinga
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
GlobeNewswire Inc.
Here's Why InflaRx N.V. (IFRX) Looks Ripe for Bottom Fishing
Zacks Investment Research
InflaRx N.V. Stock (IFRX) Financials Data
InflaRx N.V. (IFRX) Net Income 2024
IFRX net income (TTM) was -$46.12 million for the quarter ending December 31, 2023, a -46.85% decrease year-over-year.
InflaRx N.V. (IFRX) Cash Flow 2024
IFRX recorded a free cash flow (TTM) of -$41.02 million for the quarter ending December 31, 2023, a -14.73% decrease year-over-year.
InflaRx N.V. (IFRX) Earnings per Share 2024
IFRX earnings per share (TTM) was -$0.8642 for the quarter ending December 31, 2023, a -21.07% decline year-over-year.
About InflaRx N.V.
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases. It also develops IFX-2 for the treatment of chronic inflammation and autoimmune diseases. The company has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
3.18%
Cap:
|
Volume (24h):